NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today upgraded shares of Quest Diagnostics and Laboratory Corporation of America to Buy ratings on expectations that visits to primary care physicians and laboratory testing will increase in 2015 over 2014 levels. 

Analyst Mark Massaro upgraded the ratings for both companies from prior Hold ratings. He also increased his price target on Quest to $82 from an earlier $63 target, and the price target on LabCorp to $145 from $100. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.